Characterization of a newly established endometrial stromal sarcoma cell line

Gunawan, Bastian; Braun, S.; Cortés, Marta Haro; Bergmann, Frank; Karl, C.; Füzesi, L.

doi:10.1002/(sici)1097-0215(19980729)77:3<424::aid-ijc19>3.0.co;2-7

Cited by 22 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ESS-1 cells (cell line of a human ESS) were purchased from German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). This cell line, established by Gunawan et al (26), shows mainly a mesenchymal phenotype and focal multilayered growth pattern and is not tumorigenic in nude mice. For in vitro experiments, the cells were grown in RPMI 1640 supplemented with heat-inactivated FCS (10%, v/v), 2.2 g/L sodium bicarbonate, 100 units/mL penicillin, and 100 Ag/mL streptomycin and cultured under standard conditions (37jC, 5% CO 2 , and 95% humidity).…”

Section: Methodsmentioning

confidence: 99%

Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells

Hrzenjak¹,

Moinfar²,

Kremser³

et al. 2006

Molecular Cancer Therapeutics

145

108

View full text Add to dashboard Cite

Covalent modifications of histone proteins, in particular deacetylation of lysine residues, are important for the regulation of gene transcription both in normal and malignant cells. These processes are controlled by histone acetyltransferases and histone deacetylases (HDAC) and have up to now not been described in solid mesenchymal tumors. The present study shows differences in the HDAC1 and HDAC2 expression in endometrial stromal sarcomas (ESS) and a cognate cell line (ESS-1) compared with nonneoplastic endometrial stroma. We show for the first time that HDAC2 expression is consistently increased in ESS. In contrast, HDAC1 expression is generally lower than HDAC2 both in nonneoplastic stroma and in ESS, suggesting that these two proteins, although closely related, are regulated in different ways. In vitro experiments with an ESS cell line showed that valproate, an inhibitor of the class I HDACs, led to significant HDAC2 decrease and to cell differentiation. HDAC2 inhibition in ESS-1 cells caused significant changes in the cell cycle by inhibiting G 1 -S transition and influencing expression of p21 WAF1 and cyclin D1. Moreover, in ESS-1 cells, increased expression of the p21 WAF1 was associated with reduction of HDAC2 expression after transfection with small interfering RNA directed against HDAC2. Our results suggest that HDAC2 might be considered as potential drug target in the therapy of ESS and that HDAC inhibitors should be further evaluated in clinical trials in ESS. [Mol Cancer Ther 2006;5(9):2203 -10]

show abstract

Section: Methodsmentioning

confidence: 99%

Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells

Hrzenjak¹,

Moinfar²,

Kremser³

et al. 2006

Molecular Cancer Therapeutics

145

108

View full text Add to dashboard Cite

show abstract

“…There have been a number of karyotypic abnormalities reported in ESTs 2,5,9,13,[15][16][17][18]21,25,30,31,33,34,41,42,44 ; most have been identified in individual tumors, but a recurrent translocation, t(7;17)(p15;q21), has been identified cytogenetically in several reports. 10,20,40,45 Koontz et al 29 identified the genes involved in this translocation, encoding 2 novel proteins with zinc-finger motifs, JAZF1 (Juxtaposed to Another Zinc-Finger gene) on chromosome 7 and JJAZ1 (Joined to JAZF1, also known as SUZ12) on chromosome 17.…”

mentioning

confidence: 99%

Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCT) Lack the JAZF1-JJAZ1 Translocation Frequently Seen in Endometrial Stromal Tumors

Staats

García

Dias‐Santagata

et al. 2009

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a rare uterine neoplasm composed predominantly or exclusively of cells which resemble those seen in sex cord tumors of the ovary. Since its initial morphologic description, it has been unclear whether UTROSCT represents a variant within the spectrum of endometrial stromal tumors (ESTs), which may rarely exhibit areas of sex cord-like differentiation, or whether it is a distinct uterine neoplasm unrelated to ESTs. Recently, several studies have revealed a recurrent t(7;17) translocation resulting in a JAZF1-JJAZ1 gene fusion in over 60% of EST and its variants, including 2 out of 4 endometrial stromal tumors with sex cord-like elements (ESTSCLE). We examined UTROSCTs for evidence of the JAZF1-JJAZ1 gene fusion by fluorescence in situ hybridization and by reverse transcriptase polymerase chain reaction in 24 and 20 cases, respectively. The JAZF1-JJAZ1 gene fusion was not identified in any tumor by either method. Although we cannot entirely exclude that UTROSCT represents a variant of ESTSCLE which lacks this translocation, our findings suggest that UTROSCT does not share the genetic mechanism common to the majority of ESTs with or without sex cord-like differentiation, and therefore most likely represents a distinct neoplasm unrelated to ESTSCLE.

show abstract

“…On day 21, there was a tumorous ulceration in one placebo case. Although the surface area of the tumor was well supplied with blood vessels, we observed tumors larger then 800 mm 3 to be most often necrotic in their center. However, this can be expected from the rapid tumor growth and inadequate blood supply of deeper tumor 6 MES-SA cells were injected subcutaneously in NudeFoxn1 nu/nu mice (n = 14) and four days later mice were injected either placebo (HOP-β-CD) or 50 mg/kg/day vorinostat dissolved in HOP-β-CD for a total of 21 days.…”

Section: Vorinostat Inhibits Tumor Growth In Xenograft Micementioning

confidence: 63%

248 Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo

Hrzenjak¹,

Moinfar²,

Kremser³

et al. 2010

European Journal of Cancer Supplements

View full text Add to dashboard Cite

Characterization of a newly established endometrial stromal sarcoma cell line

Cited by 22 publications

References 18 publications

Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells

Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells

Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCT) Lack the JAZF1-JJAZ1 Translocation Frequently Seen in Endometrial Stromal Tumors

248 Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo

Contact Info

Product

Resources

About